I. Vaincre-la-mucoviscidose, Registre français de la mucoviscidose ? Bilan des données, 2010.

O. Sullivan, B. Freedman, and S. , Cystic fibrosis, The Lancet, vol.373, issue.9678, pp.1891-904, 2009.
DOI : 10.1016/S0140-6736(09)60327-5

R. Groot, . De, and A. Smith, Antibiotic Pharmacokinetics in Cystic Fibrosis, Clinical Pharmacokinetics, vol.13, issue.4, pp.228-53, 1987.
DOI : 10.2165/00003088-198713040-00002

E. Rey, J. Tréluyer, and G. Pons, Drug Disposition in Cystic Fibrosis, Clinical Pharmacokinetics, vol.35, issue.4, pp.313-342, 1998.
DOI : 10.2165/00003088-199835040-00004

D. Touw, Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis, Pharmacy World and Science, vol.20, issue.4, pp.149-60, 1998.
DOI : 10.1023/A:1008634911114

B. Hamelin, N. Moore, C. Knupp, M. Ruel, F. Vallée et al., Cefepime pharmacokinetics in cystic fibrosis, Pharmacotherapy, vol.13, issue.5, pp.465-70, 1993.

J. Leeder, M. Spino, A. Isles, A. Tesoro, R. Gold et al., Ceftazidime disposition in acute and stable cystic fibrosis, Clinical Pharmacology and Therapeutics, vol.36, issue.3, pp.355-62, 1984.
DOI : 10.1038/clpt.1984.187

M. Spino, R. Chai, A. Isles, J. Thiessen, A. Tesoro et al., Cloxacillin absorption and disposition in cystic fibrosis, The Journal of Pediatrics, vol.105, issue.5, pp.829-864, 1984.
DOI : 10.1016/S0022-3476(84)80317-0

B. Christensson, B. Ljungberg, L. Eriksson, and I. Nilsson-ehle, Pharmacokinetics of Meropenem in Patients with Cystic Fibrosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.17, issue.12, pp.873-879, 1998.
DOI : 10.1007/s100960050211

P. Lietman, Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Beta-lactam antibiotics, Chest, vol.94, issue.2, pp.115-120, 1988.
DOI : 10.1378/chest.94.2.115S

A. Horrevorts, O. Driessen, M. Michel, and K. Kerrebijn, Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics, Chest, vol.94, issue.2, 1988.
DOI : 10.1378/chest.94.2.120S

H. Kelly, R. Menendez, L. Fan, and S. Murphy, Pharmacokinetics of tobramycin in cystic fibrosis, The Journal of Pediatrics, vol.100, issue.2, pp.318-339, 1982.
DOI : 10.1016/S0022-3476(82)80664-1

D. Campbell, A. Thomson, and B. Stack, Population Pharmacokinetics of Aminoglycoside Antibiotics in Patients With Cystic Fibrosis, Therapeutic Drug Monitoring, vol.21, issue.3, pp.281-289, 1999.
DOI : 10.1097/00007691-199906000-00004

L. Bauer, J. Piecoro, . Jr, H. Wilson, and R. Blouin, Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis, Clin Pharm, vol.2, issue.3, pp.262-266, 1983.

I. Sermet-gaudelus, A. Hulin, A. Ferroni, C. Silly, J. Gaillard et al., L'antibioth??rapie dans la mucoviscidose. I. Particularit??s pharmacologiques des antibiotiques, Archives de P??diatrie, vol.7, issue.5, pp.519-547, 2000.
DOI : 10.1016/S0929-693X(00)89009-0

A. Nationale-d, Accréditation et d'Évaluation en Santé, Société française de pédiatrie. Conférence de consensus -Prise en charge du patient atteint de mucoviscidose -Pneumologie et infectiologie, 2002.

D. Hayes, . Jr, D. Feola, B. Murphy, R. Kuhn et al., Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis, American Journal of Health-System Pharmacy, vol.68, issue.4, pp.319-341, 2011.
DOI : 10.2146/ajhp100100

J. Orens, M. Estenne, S. Arcasoy, J. Conte, P. Corris et al., International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update???A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.25, issue.7, pp.745-55, 2006.
DOI : 10.1016/j.healun.2006.03.011

B. Philippe, C. Dromer, J. Mornex, J. Velly, and M. Stern, Quand le pneumologue doit-il envisager la greffe pulmonaire pour un de ses patients???, Revue des Maladies Respiratoires, vol.26, issue.4, pp.423-435, 2009.
DOI : 10.1016/S0761-8425(09)74047-1

S. Quétant, T. Rochat, and C. Pison, R??sultats de la transplantation pulmonaire, Revue des Maladies Respiratoires, vol.27, issue.8, pp.921-959, 2010.
DOI : 10.1016/j.rmr.2010.08.001

R. Dupuis and E. Sredzienski, Tobramycin Pharmacokinetics in Patients with Cystic Fibrosis Preceding and Following Lung Transplantation, Therapeutic Drug Monitoring, vol.21, issue.2, pp.161-166, 1999.
DOI : 10.1097/00007691-199904000-00004

K. Walsh, G. Davis, D. Hayes, . Jr, R. Kuhn et al., Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation, Transplant Infectious Disease, vol.123, issue.6, pp.616-637, 2011.
DOI : 10.1111/j.1399-3062.2011.00651.x

. Afssaps, Mise au point sur le bon usage des aminosides administrés par voie injectable : gentamicine, tobramycine, netilmicine, amikacine, 2011.

M. Jelassi, A. Benlmouden, S. Lefeuvre, J. Mainardi, and E. Billaud, Niveau de preuve pour le suivi th??rapeutique pharmacologique de la vancomycine, Th??rapie, vol.66, issue.1, pp.29-37, 2011.
DOI : 10.2515/therapie/2011005

M. Rybak, B. Lomaestro, J. Rotschafer, R. Moellering, W. Craig et al., Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health???System Pharmacists, and the Society of Infectious Diseases Pharmacists, Clinical Infectious Diseases, vol.49, issue.3, pp.325-332, 2009.
DOI : 10.1086/600877

A. Boulamery, N. Venisse, L. Guellec, and C. , Niveau de preuve du suivi th??rapeutique pharmacologique de la teicoplanine, Th??rapie, vol.66, issue.1, pp.45-50, 2011.
DOI : 10.2515/therapie/2011003

A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille et al., Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-212, 2008.
DOI : 10.1086/524669

D. Andes, A. Pascual, and O. Marchetti, Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications, Antimicrobial Agents and Chemotherapy, vol.53, issue.1, pp.24-34, 2009.
DOI : 10.1128/AAC.00705-08

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612175

N. Soulsby, H. Greville, K. Coulthard, and C. Doecke, What is the best method for measuring renal function in adults and children with cystic fibrosis?, Journal of Cystic Fibrosis, vol.9, issue.2, pp.124-133, 2010.
DOI : 10.1016/j.jcf.2009.12.002

M. Hornum, M. Iversen, I. Steffensen, P. Hovind, J. Carlsen et al., Cr-EDTA Measured Renal Function During the First Weeks Following Lung Transplantation, American Journal of Transplantation, vol.269, issue.4 Pt 2, pp.1420-1426, 2009.
DOI : 10.1111/j.1600-6143.2009.02627.x

S. Hmiel, A. Beck, M. De-la-morena, and S. Sweet, Progressive Chronic Kidney Disease After Pediatric Lung Transplantation, American Journal of Transplantation, vol.48, issue.7, pp.1739-1786, 2005.
DOI : 10.1093/ndt/16.8.1681

O. Connell, O. Plant, W. Plant, and B. , Mechanisms of the rapid decline in glomerular filtration rate following lung transplantation in patients with cystic fibrosis, Am. J. Transplant, vol.10, issue.4, pp.954-955, 2010.

R. Gaston, Chronic Calcineurin Inhibitor Nephrotoxicity: Reflections on an Evolving Paradigm, Clinical Journal of the American Society of Nephrology, vol.4, issue.12, pp.2029-2063, 2009.
DOI : 10.2215/CJN.03820609

M. Naesens, D. Kuypers, and M. Sarwal, Calcineurin Inhibitor Nephrotoxicity, Clinical Journal of the American Society of Nephrology, vol.4, issue.2, pp.481-508, 2009.
DOI : 10.2215/CJN.04800908

URL : http://cjasn.asnjournals.org/content/4/2/481.full.pdf

S. Arora, E. Gude, V. Sigurdardottir, S. Mortensen, H. Eiskjaer et al., Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate, The Journal of Heart and Lung Transplantation, vol.31, issue.3, pp.259-65, 2012.
DOI : 10.1016/j.healun.2011.12.010

L. Gullestad, M. Iversen, S. Mortensen, H. Eiskjaer, G. Riise et al., Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial, Transplantation, vol.89, issue.7, pp.864-72, 2010.
DOI : 10.1097/TP.0b013e3181cbac2d

V. Costache, O. Chavanon, C. St-raymond, C. Sessa, M. Durand et al., Dramatic Improvement in Survival After Lung Transplantation Over Time: A Single Center Experience, Transplantation Proceedings, vol.41, issue.2, pp.687-91, 2009.
DOI : 10.1016/j.transproceed.2008.12.016

URL : https://hal.archives-ouvertes.fr/inserm-00387548

I. Vaincre-la-mucoviscidose, Registre français de la mucoviscidose ? Bilan des données, 2010.

X. Dray, R. Kanaan, T. Bienvenu, N. Desmazes-dufeu, D. Dusser et al., Malnutrition in adults with cystic fibrosis, European Journal of Clinical Nutrition, vol.59, issue.1, pp.152-156, 2005.
DOI : 10.1038/sj.ejcn.1602039

P. Aurora, B. Whitehead, A. Wade, J. Bowyer, P. Whitmore et al., Lung transplantation and life extension in children with cystic fibrosis, The Lancet, vol.354, issue.9190, pp.1591-1594, 1999.
DOI : 10.1016/S0140-6736(99)03031-7

T. Egan, F. Detterbeck, M. Mill, L. Paradowski, R. Lackner et al., Improved results of lung transplantation for patients with cystic fibrosis, The Journal of Thoracic and Cardiovascular Surgery, vol.109, issue.2, pp.224-234, 1995.
DOI : 10.1016/S0022-5223(95)70383-7

M. Iversen, C. Burton, S. Vand, L. Skovfoged, J. Carlsen et al., Aspergillus infection in lung transplant patients: incidence and prognosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.7, issue.1, pp.879-86, 2007.
DOI : 10.1007/s10096-007-0376-3

I. Neuringer, Posttransplant Lymphoproliferative Disease after Lung Transplantation, Clinical and Developmental Immunology, vol.12, issue.4, p.430209, 2013.
DOI : 10.1182/blood-2010-03-274076

URL : http://doi.org/10.1155/2013/430209

D. Touw, Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis, Pharmacy World and Science, vol.20, issue.4, pp.149-60, 1998.
DOI : 10.1023/A:1008634911114

R. Groot, . De, and A. Smith, Antibiotic Pharmacokinetics in Cystic Fibrosis, Clinical Pharmacokinetics, vol.13, issue.4, pp.228-53, 1987.
DOI : 10.2165/00003088-198713040-00002

A. Nationale-d, Accréditation et d'Évaluation en Santé, Société française de pédiatrie. Conférence de consensus -Prise en charge du patient atteint de mucoviscidose -Pneumologie et infectiologie, 2002.

O. Sullivan, B. Freedman, and S. , Cystic fibrosis, The Lancet, vol.373, issue.9678, pp.1891-904, 2009.
DOI : 10.1016/S0140-6736(09)60327-5

I. Sermet-gaudelus, G. Lenoir, P. Berche, C. Ricour, F. Lacaille et al., Mucoviscidose??: physiopathologie, g??n??tique, aspects cliniques et th??rapeutiques, EMC - P??diatrie - Maladies infectieuses, vol.1, issue.1, pp.60-70, 2002.
DOI : 10.1016/S1637-5017(06)74491-X

B. Rosenstein and G. Cutting, WHAT IS A CYSTIC FIBROSIS DIAGNOSIS?, Clinics in Chest Medicine, vol.19, issue.3, pp.589-95, 1998.
DOI : 10.1016/S0272-5231(05)70091-5

D. Boeck, K. Wilschanski, M. Castellani, C. Taylor, C. Cuppens et al., Cystic fibrosis: terminology and diagnostic algorithms, Thorax, vol.61, issue.7, pp.627-662, 2006.
DOI : 10.1136/thx.2005.043539

J. Crossley, R. Elliott, and P. Smith, DRIED-BLOOD SPOT SCREENING FOR CYSTIC FIBROSIS IN THE NEWBORN, The Lancet, vol.313, issue.8114, pp.472-476, 1979.
DOI : 10.1016/S0140-6736(79)90825-0

P. Desmarquest, D. Feldmann, A. Tamalat, M. Boule, B. Fauroux et al., Genotype Analysis and Phenotypic Manifestations of Children With Intermediate Sweat Chloride Test Results, Chest, vol.118, issue.6, pp.1591-1598, 2000.
DOI : 10.1378/chest.118.6.1591

H. Autorité and D. Santé, Le dépistage néonatal systématique de la mucoviscidose en France : état des lieux et persepectives après 5 ans de fonctionnement, 2009.

E. Girodon-boulandet and C. Costa, Génétique de la mucoviscidose, Médecine Thérapeutique pédiatrique, vol.8, issue.3, pp.126-160

M. Welsh and A. Smith, Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis, Cell, vol.73, issue.7, pp.1251-1255, 1993.
DOI : 10.1016/0092-8674(93)90353-R

M. Welsh, The path of discovery in understanding the biology of cystic fibrosis and approaches to therapy, Am. J. Gastroenterol, vol.89, pp.97-105, 1994.

B. Rosenstein, Nonclassic cystic fibrosis: A clinical conundrum, Pediatric Pulmonology, vol.137, issue.1, pp.10-12, 2003.
DOI : 10.1002/ppul.10286

I. Vaincre-la-mucoviscidose, Registre français de la mucoviscidose ? Bilan des données, 2005.

J. Dodge and D. Turck, Cystic fibrosis: Nutritional consequences and management, Best Practice & Research Clinical Gastroenterology, vol.20, issue.3, pp.531-577, 2006.
DOI : 10.1016/j.bpg.2005.11.006

A. Chryssostalis, D. Hubert, J. Coste, R. Kanaan, P. Burgel et al., Liver disease in adult patients with cystic fibrosis: A frequent and independent prognostic factor associated with death or lung transplantation, Journal of Hepatology, vol.55, issue.6, pp.1377-82, 2011.
DOI : 10.1016/j.jhep.2011.03.028

A. Brennan, D. Geddes, K. Gyi, and E. Baker, Clinical importance of cystic fibrosis-related diabetes, Journal of Cystic Fibrosis, vol.3, issue.4, pp.209-231, 2004.
DOI : 10.1016/j.jcf.2004.08.001

C. Haworth, A. Webb, J. Egan, P. Selby, P. Hasleton et al., Bone Histomorphometry in Adult Patients With Cystic Fibrosis, Chest, vol.118, issue.2, pp.434-443, 2000.
DOI : 10.1378/chest.118.2.434

A. Pauwels, K. Blondeau, L. Dupont, and D. Sifrim, Mechanisms of Increased Gastroesophageal Reflux in Patients With Cystic Fibrosis, The American Journal of Gastroenterology, vol.91, issue.9, pp.1346-53, 2012.
DOI : 10.3109/00365528809090232

A. Lyon and D. Bilton, Fertility issues in cystic fibrosis, Paediatric Respiratory Reviews, vol.3, issue.3, pp.236-276, 2002.
DOI : 10.1016/S1526-0542(02)00184-7

G. Döring, S. Conway, H. Heijerman, M. Hodson, N. Høiby et al., Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus, European Respiratory Journal, vol.16, issue.4, pp.749-67, 2000.
DOI : 10.1034/j.1399-3003.2000.16d30.x

S. Razvi, L. Quittell, A. Sewall, H. Quinton, B. Marshall et al., Respiratory Microbiology of Patients With Cystic Fibrosis in the United States, 1995 to 2005, Chest, vol.136, issue.6, pp.1554-60, 1995.
DOI : 10.1378/chest.09-0132

R. Amin, A. Dupuis, S. Aaron, and F. Ratjen, The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Patients With Cystic Fibrosis, Chest, vol.137, issue.1, pp.171-177, 2010.
DOI : 10.1378/chest.09-1103

R. Kraemer, N. Deloséa, P. Ballinari, S. Gallati, and R. Crameri, Effect of Allergic Bronchopulmonary Aspergillosis on Lung Function in Children with Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.11, pp.1211-1231, 2006.
DOI : 10.1164/rccm.200603-423OC

M. Miller, R. Crapo, J. Hankinson, V. Brusasco, F. Burgos et al., General considerations for lung function testing, European Respiratory Journal, vol.26, issue.1, pp.153-61, 2005.
DOI : 10.1183/09031936.05.00034505

M. Konstan, W. Morgan, S. Butler, D. Pasta, M. Craib et al., Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis, The Journal of Pediatrics, vol.151, issue.2, pp.134-139, 2007.
DOI : 10.1016/j.jpeds.2007.03.006

J. Courtney, J. Bradley, J. Mccaughan, O. Connor, T. Shortt et al., Predictors of mortality in adults with cystic fibrosis, Pediatric Pulmonology, vol.85, issue.6, pp.525-557, 2007.
DOI : 10.1002/ppul.20619

A. Munck, C. Sahler, M. Briard, M. Vidailhet, and J. Farriaux, Le programme fran??ais de d??pistage n??onatal syst??matique dans la mucoviscidose??: r??sultats et interrogations sur un million de tests, Immuno-analyse & Biologie Sp??cialis??e, vol.20, issue.4, pp.228-261, 2005.
DOI : 10.1016/j.immbio.2005.05.001

. Vaincre-la-mucoviscidose-chiffres-clés, Consulté le 19 février 2013

D. Georges, M. Guittard, C. Bozon, D. , and C. F. , Les bases mol??culaires de la mucoviscidose en France : plus de 300 mutations et 506 g??notypes diff??rents sont en cause., m??decine/sciences, vol.14, issue.12, pp.1413-1434, 1998.
DOI : 10.4267/10608/984

E. Mckone, S. Emerson, K. Edwards, and M. Aitken, Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study, The Lancet, vol.361, issue.9370, pp.1671-1677, 2003.
DOI : 10.1016/S0140-6736(03)13368-5

E. Dasenbrook, W. Checkley, C. Merlo, M. Konstan, N. Lechtzin et al., Association Between Respiratory Tract Methicillin-Resistant S<emph type="ital">taphylococcus aureus</emph> and Survival in Cystic Fibrosis, JAMA, vol.303, issue.23, pp.2386-92, 2010.
DOI : 10.1001/jama.2010.791

R. Wilmott, S. Tyson, and D. Matthew, Cystic Fibrosis Survival Rates, American Journal of Diseases of Children, vol.139, issue.7, pp.669-71, 19601985.
DOI : 10.1001/archpedi.1985.02140090031019

P. Flume, O. Sullivan, B. Robinson, K. Goss, C. Mogayzel et al., Cystic Fibrosis Pulmonary Guidelines, American Journal of Respiratory and Critical Care Medicine, vol.176, issue.10, pp.957-69, 2007.
DOI : 10.1164/rccm.200705-664OC

Y. Duijvestijn and P. Brand, Systematic review of N-acetylcysteine in cystic fibrosis, Acta Paediatrica, vol.331, issue.Suppl 111, pp.38-41, 19921999.
DOI : 10.1111/j.1651-2227.1999.tb01265.x

H. Eigen, B. Rosenstein, S. Fitzsimmons, and D. Schidlow, A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis, The Journal of Pediatrics, vol.126, issue.4, pp.515-538, 1995.
DOI : 10.1016/S0022-3476(95)70343-8

H. Stutman, J. Lieberman, E. Nussbaum, and M. Marks, Antibiotic prophylaxis in infants and young children with cystic fibrosis: A randomized controlled trial, The Journal of Pediatrics, vol.140, issue.3, pp.299-305, 2002.
DOI : 10.1067/mpd.2002.121930

B. Ramsey, M. Pepe, J. Quan, K. Otto, A. Montgomery et al., Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis, New England Journal of Medicine, vol.340, issue.1, pp.23-30, 1999.
DOI : 10.1056/NEJM199901073400104

T. Jensen, S. Pedersen, S. Garne, C. Heilmann, N. Høiby et al., lung infection, Journal of Antimicrobial Chemotherapy, vol.19, issue.6, pp.831-839, 1987.
DOI : 10.1093/jac/19.6.831

M. Hodson, C. Gallagher, and J. Govan, A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis, European Respiratory Journal, vol.20, issue.3, pp.658-64, 2002.
DOI : 10.1183/09031936.02.00248102

M. Shinkai, M. Henke, and B. Rubin, Macrolide antibiotics as immunomodulatory medications: Proposed mechanisms of action, Pharmacology & Therapeutics, vol.117, issue.3, pp.393-405, 2008.
DOI : 10.1016/j.pharmthera.2007.11.001

L. Saiman, N. Mayer-hamblett, P. Campbell, and B. Marshall, Heterogeneity of Treatment Response to Azithromycin in Patients with Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.8, pp.1008-1020, 2005.
DOI : 10.1164/rccm.200502-218OC

L. Saiman, M. Anstead, N. Mayer-hamblett, L. Lands, M. Kloster et al., Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With <emph type="ital">Pseudomonas aeruginosa</emph><subtitle>A Randomized Controlled Trial</subtitle>, JAMA, vol.303, issue.17, pp.1707-1722, 2010.
DOI : 10.1001/jama.2010.563

D. Stevens, R. Moss, V. Kurup, A. Knutsen, P. Greenberger et al., Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis???State of the Art: Cystic Fibrosis Foundation Consensus Conference, Clinical Infectious Diseases, vol.37, issue.s3, pp.225-264, 2003.
DOI : 10.1086/376525

M. Ferrin, J. Zuckerman, A. Meagher, and E. Blumberg, Successful treatment of methicillin-resistantStaphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis, Pediatric Pulmonology, vol.54, issue.3, pp.221-224, 2002.
DOI : 10.1002/ppul.10062

D. Betton, A. Gairard-dory, R. Kessler, F. Jehl, V. Rosner et al., Utilisation du lin??zolide dans le traitement des infections broncho-pulmonaires du patient adulte atteint par la mucoviscidose, Revue de Pneumologie Clinique, vol.62, issue.6, pp.374-382, 2006.
DOI : 10.1016/S0761-8417(06)75470-0

D. Serisier, G. Jones, and M. Carroll, Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid, Journal of Cystic Fibrosis, vol.3, issue.1, p.61, 2004.
DOI : 10.1016/j.jcf.2003.12.010

R. Gibson, J. Burns, and B. Ramsey, Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.168, issue.8, pp.918-51, 2003.
DOI : 10.1164/rccm.200304-505SO

A. Smyth, K. Tan, P. Hyman-taylor, M. Mulheran, S. Lewis et al., Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis???the TOPIC study: a randomised controlled trial, The Lancet, vol.365, issue.9459, pp.573-581, 2005.
DOI : 10.1016/S0140-6736(05)17906-9

A. Smyth and J. Bhatt, Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis, Cochrane Database Syst. Rev. Online, vol.2, p.2009, 2012.

S. Croes, A. Koop, S. Van-gils, and C. Neef, Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring, European Journal of Pharmaceutical Sciences, vol.45, issue.1-2, pp.90-100, 2012.
DOI : 10.1016/j.ejps.2011.10.022

A. Balaguer and J. González-de-dios, Home versus hospital intravenous antibiotic therapy for cystic fibrosis, Cochrane Database Syst. Rev. Online, vol.3, p.1917, 2012.
DOI : 10.1002/14651858.cd001917.pub3

M. Sinaasappel, M. Stern, J. Littlewood, S. Wolfe, G. Steinkamp et al., Nutrition in patients with cystic fibrosis: a European Consensus, Journal of Cystic Fibrosis, vol.1, issue.2, pp.51-75, 2002.
DOI : 10.1016/S1569-1993(02)00032-2

D. Borowitz, R. Baker, and V. Stallings, Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis, Journal of Pediatric Gastroenterology and Nutrition, vol.35, issue.3, pp.246-59, 2002.
DOI : 10.1097/00005176-200209000-00004

C. Bonifant, E. Shevill, and A. Chang, Vitamin A supplementation for cystic fibrosis, Cochrane Database Syst. Rev. Online, vol.8, p.6751, 2012.

L. Wolfenden, S. Judd, R. Shah, R. Sanyal, T. Ziegler et al., Vitamin D and bone health in adults with cystic fibrosis, Clinical Endocrinology, vol.163, issue.6 Suppl., pp.374-81, 2008.
DOI : 10.1111/j.1365-2265.2008.03216.x

J. Ferguson and A. Chang, Vitamin D supplementation for cystic fibrosis, Cochrane Database Syst. Rev. Online, vol.4, p.7298, 2012.

P. Flume, T. Egan, L. Paradowski, F. Detterbeck, J. Thompson et al., Infectious complications of lung transplantation. Impact of cystic fibrosis., American Journal of Respiratory and Critical Care Medicine, vol.149, issue.6, pp.1601-1608, 1994.
DOI : 10.1164/ajrccm.149.6.7516251

J. Orens, M. Estenne, S. Arcasoy, J. Conte, P. Corris et al., International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update???A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.25, issue.7, pp.745-55, 2006.
DOI : 10.1016/j.healun.2006.03.011

A. Olland, P. Falcoz, R. Kessler, and G. Massard, Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation?, Interactive CardioVascular and Thoracic Surgery, vol.13, issue.6, pp.631-635, 2011.
DOI : 10.1510/icvts.2011.271874

S. Murthy, E. Nowicki, D. Mason, M. Budev, A. Nunez et al., Pretransplant gastroesophageal reflux compromises early outcomes after lung transplantation, The Journal of Thoracic and Cardiovascular Surgery, vol.142, issue.1, pp.47-52, 2011.
DOI : 10.1016/j.jtcvs.2011.04.028

URL : http://dx.doi.org/10.1016/j.jtcvs.2011.04.028

B. Mendez, C. Davis, C. Weber, R. Joehl, and P. Fisichella, Gastroesophageal reflux disease in lung transplant patients with cystic fibrosis, The American Journal of Surgery, vol.204, issue.5, pp.21-26, 2012.
DOI : 10.1016/j.amjsurg.2012.07.019

D. , X. Gariboldi, V. Trousse, D. Grisoli, D. Gaillat et al., Techniques de transplantation bipulmonaires, Tech. Chir. -Thorax, pp.42-440, 2011.

J. Maurer, A. Frost, M. Estenne, T. Higenbottam, and A. Glanville, INTERNATIONAL GUIDELINES FOR THE SELECTION OF LUNG TRANSPLANT CANDIDATES, Transplantation, vol.66, issue.7, pp.951-957, 1998.
DOI : 10.1097/00007890-199810150-00033

I. Inci, O. Stanimirov, C. Benden, P. Kestenholz, M. Hofer et al., Lung transplantation for cystic fibrosis: a single center experience of 100 consecutive cases, European Journal of Cardio-Thoracic Surgery, vol.41, issue.2, pp.435-475, 2012.
DOI : 10.1016/j.ejcts.2011.06.017

J. Christie, L. Edwards, A. Kucheryavaya, C. Benden, A. Dipchand et al., The Registry of the International Society for Heart and Lung Transplantation: 29th Adult Lung and Heart-Lung Transplant Report???2012, The Journal of Heart and Lung Transplantation, vol.31, issue.10, pp.311073-86, 2012.
DOI : 10.1016/j.healun.2012.08.004

C. Dobbin, M. Maley, J. Harkness, R. Benn, M. Malouf et al., The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre, Journal of Hospital Infection, vol.56, issue.4, pp.277-82, 2004.
DOI : 10.1016/j.jhin.2004.01.003

R. Bonvillain, V. Valentine, G. Lombard, S. Laplace, G. Dhillon et al., Post-operative Infections in Cystic Fibrosis and Non???Cystic Fibrosis Patients After Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.26, issue.9, pp.890-897, 2007.
DOI : 10.1016/j.healun.2007.07.002

D. Hadjiliadis, M. Steele, C. Chaparro, L. Singer, T. Waddell et al., Survival of Lung Transplant Patients With Cystic Fibrosis Harboring Panresistant Bacteria Other Than Burkholderia cepacia, Compared With Patients Harboring Sensitive Bacteria, The Journal of Heart and Lung Transplantation, vol.26, issue.8, pp.834-842, 2007.
DOI : 10.1016/j.healun.2007.05.018

M. Malouf, P. Chhajed, P. Hopkins, M. Plit, J. Turner et al., Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients, The Journal of Heart and Lung Transplantation, vol.21, issue.5, pp.547-54, 2002.
DOI : 10.1016/S1053-2498(01)00407-7

G. Wiederrecht, E. Lam, S. Hung, M. Martin, and N. Sigal, The Mechanism of Action of FK-506 and Cyclosporin A, Annals of the New York Academy of Sciences, vol.43, issue.1, pp.9-19, 1993.
DOI : 10.1111/j.1749-6632.1993.tb17137.x

Y. Fan, Y. Xiao, and Y. Weng, Tacrolimus Versus Cyclosporine for Adult Lung Transplant Recipients: A Meta-Analysis, Transplantation Proceedings, vol.41, issue.5, pp.1821-1825, 2009.
DOI : 10.1016/j.transproceed.2008.11.016

H. Eisen, J. Kobashigawa, A. Keogh, R. Bourge, D. Renlund et al., Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.24, issue.5, pp.517-542, 2005.
DOI : 10.1016/j.healun.2005.02.002

L. Gullestad, M. Iversen, S. Mortensen, H. Eiskjaer, G. Riise et al., Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial, Transplantation, vol.89, issue.7, pp.864-72, 2010.
DOI : 10.1097/TP.0b013e3181cbac2d

A. Ojo, P. Held, F. Port, R. Wolfe, A. Leichtman et al., Chronic Renal Failure after Transplantation of a Nonrenal Organ, New England Journal of Medicine, vol.349, issue.10, pp.931-971, 2003.
DOI : 10.1056/NEJMoa021744

M. Naesens, D. Kuypers, and M. Sarwal, Calcineurin Inhibitor Nephrotoxicity, Clinical Journal of the American Society of Nephrology, vol.4, issue.2, pp.481-508, 2009.
DOI : 10.2215/CJN.04800908

URL : http://cjasn.asnjournals.org/content/4/2/481.full.pdf

S. Flechner, J. Kobashigawa, and G. Klintmalm, Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity, Clinical Transplantation, vol.6, issue.2, pp.1-15, 2008.
DOI : 10.1016/j.transproceed.2005.01.013

V. Audard, Remplacement des inhibiteurs de la calcineurine par des inhibiteurs du signal de prolif??ration apr??s transplantation r??nale : indications, r??sultats et inconv??nients, N??phrologie & Th??rapeutique, vol.5, issue.6, pp.395-399, 2009.
DOI : 10.1016/S1769-7255(09)73432-7

M. Spino, Pharmacokinetics of Drugs in Cystic Fibrosis, Clin. Rev. Allergy, vol.9, issue.1 2, pp.169-210, 1991.
DOI : 10.1007/978-1-4612-0475-6_11

M. Spino, R. Chai, A. Isles, J. Thiessen, A. Tesoro et al., Cloxacillin absorption and disposition in cystic fibrosis, The Journal of Pediatrics, vol.105, issue.5, pp.829-864, 1984.
DOI : 10.1016/S0022-3476(84)80317-0

C. Lee, M. Boyle, M. Diener-west, L. Brass-ernst, M. Noschese et al., Levofloxacin Pharmacokinetics in Adult Cystic Fibrosis, Chest, vol.131, issue.3, pp.796-802, 2007.
DOI : 10.1378/chest.06-1524

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075103

P. Beringer, K. Huynh, J. Kriengkauykiat, L. Bi, N. Hoem et al., Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis, Antimicrobial Agents and Chemotherapy, vol.49, issue.12, pp.5013-5020, 2005.
DOI : 10.1128/AAC.49.12.5013-5017.2005

J. Leeder, M. Spino, A. Isles, A. Tesoro, R. Gold et al., Ceftazidime disposition in acute and stable cystic fibrosis, Clinical Pharmacology and Therapeutics, vol.36, issue.3, pp.355-62, 1984.
DOI : 10.1038/clpt.1984.187

J. Bulitta, C. Landersdorfer, S. Hüttner, G. Drusano, M. Kinzig et al., Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.54, issue.3, pp.1275-82, 2010.
DOI : 10.1128/AAC.00936-09

J. Bosso, P. Townsend, J. Herbst, and J. Matsen, Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients., Antimicrobial Agents and Chemotherapy, vol.28, issue.6, pp.829-860, 1985.
DOI : 10.1128/AAC.28.6.829

A. Horrevorts, O. Driessen, M. Michel, and K. Kerrebijn, Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics, Chest, vol.94, issue.2, 1988.
DOI : 10.1378/chest.94.2.120S

D. Campbell, A. Thomson, and B. Stack, Population Pharmacokinetics of Aminoglycoside Antibiotics in Patients With Cystic Fibrosis, Therapeutic Drug Monitoring, vol.21, issue.3, pp.281-289, 1999.
DOI : 10.1097/00007691-199906000-00004

I. Sermet-gaudelus, A. Hulin, A. Ferroni, C. Silly, J. Gaillard et al., L'antibioth??rapie dans la mucoviscidose. I. Particularit??s pharmacologiques des antibiotiques, Archives de P??diatrie, vol.7, issue.5, pp.519-547, 2000.
DOI : 10.1016/S0929-693X(00)89009-0

E. Autret, S. Marchand, M. Breteau, and B. Grenier, Pharmacokinetics of amikacin in cystic fibrosis: A study of bronchial diffusion, European Journal of Clinical Pharmacology, vol.134, issue.suppl, pp.79-83, 1986.
DOI : 10.1007/BF00870991

J. Bulitta, M. Kinzig, C. Landersdorfer, U. Holzgrabe, U. Stephan et al., Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.55, issue.6, pp.2927-2963, 2011.
DOI : 10.1128/AAC.01484-10

B. Hamelin, N. Moore, C. Knupp, M. Ruel, F. Vallée et al., Cefepime pharmacokinetics in cystic fibrosis, Pharmacotherapy, vol.13, issue.5, pp.465-70, 1993.

G. Kearns, G. Mallory, . Jr, W. Crom, and W. Evans, Enhanced hepatic drug clearance in patients with cystic fibrosis, The Journal of Pediatrics, vol.117, issue.6, pp.972-981, 1990.
DOI : 10.1016/S0022-3476(05)80149-0

D. Groot, R. Hack, B. Weber, A. Chaffin, D. et al., Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study, Clinical Pharmacology and Therapeutics, vol.47, issue.1, pp.73-81, 1990.
DOI : 10.1038/clpt.1990.11

B. Christensson, B. Ljungberg, L. Eriksson, and I. Nilsson-ehle, Pharmacokinetics of Meropenem in Patients with Cystic Fibrosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.17, issue.12, pp.873-879, 1998.
DOI : 10.1007/s100960050211

A. Hedman, G. Alván, B. Strandvik, and A. Arvidsson, Increased Renal Clearance of Cefsulodin Due to Higher Glomerular Filtration Rate in Cystic Fibrosis, Clinical Pharmacokinetics, vol.18, issue.2, pp.168-75, 1990.
DOI : 10.2165/00003088-199018020-00006

A. Hedman, Y. Adan-abdi, G. Alvan, B. Strandvik, and A. Arvidsson, Influence of the Glomerular Filtration Rate on Renal Clearance of Ceftazidime in Cystic Fibrosis, Clinical Pharmacokinetics, vol.15, issue.1, pp.57-65, 1988.
DOI : 10.2165/00003088-198815010-00005

J. Bulitta, S. Duffull, C. Landersdorfer, M. Kinzig, U. Holzgrabe et al., Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers, Diagnostic Microbiology and Infectious Disease, vol.65, issue.2, pp.130-171, 2009.
DOI : 10.1016/j.diagmicrobio.2009.06.018

M. Morales, D. Falkenstein, and A. Lopes, The Cystic Fibrosis Transmembrane Regulator (CFTR) in the kidney, Anais da Academia Brasileira de Ci??ncias, vol.72, issue.3, pp.399-406, 2000.
DOI : 10.1590/S0001-37652000000300013

N. Macdonald, N. Anas, R. Peterson, R. Schwartz, J. Brooks et al., Renal clearance of gentamicin in cystic fibrosis, The Journal of Pediatrics, vol.103, issue.6, pp.985-90, 1983.
DOI : 10.1016/S0022-3476(83)80737-9

J. Levy, A. Smith, J. Koup, J. Williams-warren, and R. B. , Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study, The Journal of Pediatrics, vol.105, issue.1, pp.117-141, 1984.
DOI : 10.1016/S0022-3476(84)80375-3

G. Kearns, W. Crom, K. Karlson, . Jr, G. Mallory et al., Hepatic drug clearance in patients with mild cystic fibrosis*, Clinical Pharmacology & Therapeutics, vol.26, issue.5, pp.529-569, 1996.
DOI : 10.1016/S0009-9236(96)90181-2

W. Prescott, . Jr, and J. Nagel, Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis, Pharmacotherapy, vol.39, issue.1, pp.95-108, 2010.
DOI : 10.1097/00007691-199302000-00010

D. Hayes, . Jr, D. Feola, B. Murphy, R. Kuhn et al., Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis, American Journal of Health-System Pharmacy, vol.68, issue.4, pp.319-341, 2011.
DOI : 10.2146/ajhp100100

A. Gross, Best practice in therapeutic drug monitoring, Br. J. Clin. Pharmacol, vol.52, issue.1, pp.5-10, 2001.

P. Marquet, Suivi th??rapeutique pharmacologique pour l???adaptation de posologie des m??dicaments, Le Pharmacien Hospitalier, vol.43, issue.173, 2004.
DOI : 10.1016/S0768-9179(08)70010-5

. Afssaps, Mise au point sur le bon usage des aminosides administrés par voie injectable : gentamicine, tobramycine, netilmicine, amikacine, 2011.

M. Jelassi, A. Benlmouden, S. Lefeuvre, J. Mainardi, and E. Billaud, Niveau de preuve pour le suivi th??rapeutique pharmacologique de la vancomycine, Th??rapie, vol.66, issue.1, pp.29-37, 2011.
DOI : 10.2515/therapie/2011005

M. Rybak, B. Lomaestro, J. Rotschafer, R. Moellering, W. Craig et al., Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health???System Pharmacists, and the Society of Infectious Diseases Pharmacists, System Pharmacists, and the Society of Infectious Diseases Pharmacists, pp.325-332, 2009.
DOI : 10.1086/600877

A. Boulamery, N. Venisse, L. Guellec, and C. , Niveau de preuve du suivi th??rapeutique pharmacologique de la teicoplanine, Th??rapie, vol.66, issue.1, pp.45-50, 2011.
DOI : 10.2515/therapie/2011003

A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille et al., Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-212, 2008.
DOI : 10.1086/524669

D. Andes, A. Pascual, and O. Marchetti, Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications, Antimicrobial Agents and Chemotherapy, vol.53, issue.1, pp.24-34, 2009.
DOI : 10.1128/AAC.00705-08

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612175

M. Berge, R. Guillemain, V. Boussaud, M. Pham, C. P. Batisse et al., Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients, Transplant Infectious Disease, vol.11, issue.3, pp.211-220, 2009.
DOI : 10.1111/j.1399-3062.2009.00384.x

T. Kiser, D. Fish, and M. Zamora, Evaluation of valganciclovir pharmacokinetics in lung transplant recipients, The Journal of Heart and Lung Transplantation, vol.31, issue.2, pp.159-66, 2012.
DOI : 10.1016/j.healun.2011.11.016

G. Snell, T. Kotsimbos, B. Levvey, M. Skiba, D. Rutherford et al., Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis, Journal of Antimicrobial Chemotherapy, vol.45, issue.4, pp.511-517, 2000.
DOI : 10.1093/jac/45.4.511

R. Dupuis and E. Sredzienski, Tobramycin Pharmacokinetics in Patients with Cystic Fibrosis Preceding and Following Lung Transplantation, Therapeutic Drug Monitoring, vol.21, issue.2, pp.161-166, 1999.
DOI : 10.1097/00007691-199904000-00004

K. Walsh, G. Davis, D. Hayes, . Jr, R. Kuhn et al., Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation, Transplant Infectious Disease, vol.123, issue.6, pp.616-637, 2011.
DOI : 10.1111/j.1399-3062.2011.00651.x

F. Rougier, C. D. Maurin, M. , and M. P. , Aminoglycoside Nephrotoxicity, Current Drug Target -Infectious Disorders, vol.4, issue.2, pp.153-62, 2004.
DOI : 10.2174/1568005043340858

URL : https://hal.archives-ouvertes.fr/hal-00427524

O. Connell, O. Plant, W. Plant, and B. , Mechanisms of the rapid decline in glomerular filtration rate following lung transplantation in patients with cystic fibrosis, Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg, vol.10, issue.4, pp.954-955, 2010.

S. Arora, E. Gude, V. Sigurdardottir, S. Mortensen, H. Eiskjaer et al., Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate, The Journal of Heart and Lung Transplantation, vol.31, issue.3, pp.259-65, 2012.
DOI : 10.1016/j.healun.2011.12.010

B. Smith, D. Yogaratnam, K. Levasseur-franklin, A. Forni, and J. Fong, Introduction to Drug Pharmacokinetics in the Critically III Patient, Chest, vol.141, issue.5, pp.1327-1363, 2012.
DOI : 10.1378/chest.11-1396

C. Monchaud, B. De-winter, C. Knoop, M. Estenne, M. Reynaud-gaubert et al., Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation, Clinical Pharmacokinetics, vol.83, issue.2, pp.175-86, 2012.
DOI : 10.2165/11594760-000000000-00000

URL : https://hal.archives-ouvertes.fr/inserm-00925698

D. Winter, B. Monchaud, C. Prémaud, A. Pison, C. Kessler et al., Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients, Clinical Pharmacokinetics, vol.31, issue.3, pp.29-39, 2012.
DOI : 10.2165/11594050-000000000-00000

URL : https://hal.archives-ouvertes.fr/inserm-00639088

O. Sullivan, B. Freedman, and S. , Cystic fibrosis, The Lancet, vol.373, issue.9678, pp.1891-904, 2009.
DOI : 10.1016/S0140-6736(09)60327-5

A. Nationale-d, Accréditation et d'Évaluation en Santé, Société française de pédiatrie. Conférence de consensus -Prise en charge du patient atteint de mucoviscidose -Pneumologie et infectiologie, 2002.

E. Rey, J. Tréluyer, and G. Pons, Drug Disposition in Cystic Fibrosis, Clinical Pharmacokinetics, vol.35, issue.4, pp.313-342, 1998.
DOI : 10.2165/00003088-199835040-00004

D. Touw, Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis, Pharmacy World and Science, vol.20, issue.4, pp.149-60, 1998.
DOI : 10.1023/A:1008634911114

J. Orens, M. Estenne, S. Arcasoy, J. Conte, P. Corris et al., International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update???A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.25, issue.7, pp.745-55, 2006.
DOI : 10.1016/j.healun.2006.03.011

P. Aurora, B. Whitehead, A. Wade, J. Bowyer, P. Whitmore et al., Lung transplantation and life extension in children with cystic fibrosis, The Lancet, vol.354, issue.9190, pp.1591-1594, 1999.
DOI : 10.1016/S0140-6736(99)03031-7

S. Quétant, T. Rochat, and C. Pison, R??sultats de la transplantation pulmonaire, Revue des Maladies Respiratoires, vol.27, issue.8, pp.921-959, 2010.
DOI : 10.1016/j.rmr.2010.08.001

R. Dupuis and E. Sredzienski, Tobramycin Pharmacokinetics in Patients with Cystic Fibrosis Preceding and Following Lung Transplantation, Therapeutic Drug Monitoring, vol.21, issue.2, pp.161-166, 1999.
DOI : 10.1097/00007691-199904000-00004

K. Walsh, G. Davis, D. Hayes, . Jr, R. Kuhn et al., Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation, Transplant Infectious Disease, vol.123, issue.6, pp.616-637, 2011.
DOI : 10.1111/j.1399-3062.2011.00651.x

I. Vaincre-la-mucoviscidose, Registre français de la mucoviscidose ? Bilan des données, 2010.

H. Mann, D. Canafax, R. Cipolle, C. Daniels, D. Zaske et al., Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis, Pediatric Pulmonology, vol.103, issue.5, pp.238-281, 1985.
DOI : 10.1002/ppul.1950010504

D. Hayes, . Jr, D. Feola, B. Murphy, R. Kuhn et al., Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis, American Journal of Health-System Pharmacy, vol.68, issue.4, pp.319-341, 2011.
DOI : 10.2146/ajhp100100

D. Adeboyeku, A. Jones, and M. Hodson, Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis, Journal of Cystic Fibrosis, vol.10, issue.1, pp.25-30, 2011.
DOI : 10.1016/j.jcf.2010.09.003

A. Smyth, K. Tan, P. Hyman-taylor, M. Mulheran, S. Lewis et al., Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis???the TOPIC study: a randomised controlled trial, The Lancet, vol.365, issue.9459, pp.573-581, 2005.
DOI : 10.1016/S0140-6736(05)17906-9

W. Prescott, . Jr, and J. Nagel, Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis, Pharmacotherapy, vol.39, issue.1, pp.95-108, 2010.
DOI : 10.1097/00007691-199302000-00010

P. Beringer, A. Vinks, R. Jelliffe, and B. Shapiro, Pharmacokinetics of Tobramycin in Adults with Cystic Fibrosis: Implications for Once-Daily Administration, Antimicrobial Agents and Chemotherapy, vol.44, issue.4, pp.809-822, 2000.
DOI : 10.1128/AAC.44.4.809-813.2000

I. Sermet-gaudelus, A. Hulin, A. Ferroni, C. Silly, J. Gaillard et al., L'antibioth??rapie dans la mucoviscidose. I. Particularit??s pharmacologiques des antibiotiques, Archives de P??diatrie, vol.7, issue.5, pp.519-547, 2000.
DOI : 10.1016/S0929-693X(00)89009-0

R. Groot, . De, and A. Smith, Antibiotic Pharmacokinetics in Cystic Fibrosis, Clinical Pharmacokinetics, vol.13, issue.4, pp.228-53, 1987.
DOI : 10.2165/00003088-198713040-00002

J. Prandota, Clinical Pharmacology of Antibiotics and Other Drugs in Cystic Fibrosis, Drugs, vol.35, issue.5, pp.542-78, 1988.
DOI : 10.2165/00003495-198835050-00004

J. Bulitta, M. Kinzig, C. Landersdorfer, U. Holzgrabe, U. Stephan et al., Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.55, issue.6, pp.2927-2963, 2011.
DOI : 10.1128/AAC.01484-10

J. Bulitta, S. Duffull, C. Landersdorfer, M. Kinzig, U. Holzgrabe et al., Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers, Diagnostic Microbiology and Infectious Disease, vol.65, issue.2, pp.130-171, 2009.
DOI : 10.1016/j.diagmicrobio.2009.06.018

J. Bulitta, C. Landersdorfer, S. Hüttner, G. Drusano, M. Kinzig et al., Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.54, issue.3, pp.1275-82, 2010.
DOI : 10.1128/AAC.00936-09

J. Bulitta, S. Duffull, M. Kinzig-schippers, U. Holzgrabe, U. Stephan et al., Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.51, issue.7, pp.2497-507, 2007.
DOI : 10.1128/AAC.01477-06

B. Christensson, B. Ljungberg, L. Eriksson, and I. Nilsson-ehle, Pharmacokinetics of Meropenem in Patients with Cystic Fibrosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.17, issue.12, pp.873-879, 1998.
DOI : 10.1007/s100960050211

C. Lee, M. Boyle, M. Diener-west, L. Brass-ernst, M. Noschese et al., Levofloxacin Pharmacokinetics in Adult Cystic Fibrosis, Chest, vol.131, issue.3, pp.796-802, 2007.
DOI : 10.1378/chest.06-1524

J. Bosso, P. Flume, and S. Gray, Linezolid Pharmacokinetics in Adult Patients with Cystic Fibrosis, Antimicrobial Agents and Chemotherapy, vol.48, issue.1, pp.281-285, 2004.
DOI : 10.1128/AAC.48.1.281-284.2004

J. Levy, A. Smith, J. Koup, J. Williams-warren, and R. B. , Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study, The Journal of Pediatrics, vol.105, issue.1, pp.117-141, 1984.
DOI : 10.1016/S0022-3476(84)80375-3

J. Bosso, P. Townsend, J. Herbst, and J. Matsen, Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients., Antimicrobial Agents and Chemotherapy, vol.28, issue.6, pp.829-860, 1985.
DOI : 10.1128/AAC.28.6.829

L. Bauer, J. Piecoro, . Jr, H. Wilson, and R. Blouin, Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis, Clin Pharm, vol.2, issue.3, pp.262-266, 1983.

L. Hendeles, R. Iafrate, P. Stillwell, and J. Mangos, Individualizing gentamicin dosage in patients with cystic fibrosis: Limitations to pharmacokinetic approach, The Journal of Pediatrics, vol.110, issue.2, pp.303-313, 1987.
DOI : 10.1016/S0022-3476(87)80178-6

G. Kearns, B. Hilman, and J. Wilson, Dosing implications of altered gentamicin disposition in patients with cystic fibrosis, The Journal of Pediatrics, vol.100, issue.2, pp.312-320, 1982.
DOI : 10.1016/S0022-3476(82)80663-X

H. Kelly, R. Menendez, L. Fan, and S. Murphy, Pharmacokinetics of tobramycin in cystic fibrosis, The Journal of Pediatrics, vol.100, issue.2, pp.318-339, 1982.
DOI : 10.1016/S0022-3476(82)80664-1

D. Campbell, A. Thomson, and B. Stack, Population Pharmacokinetics of Aminoglycoside Antibiotics in Patients With Cystic Fibrosis, Therapeutic Drug Monitoring, vol.21, issue.3, pp.281-289, 1999.
DOI : 10.1097/00007691-199906000-00004

T. Egan, F. Detterbeck, M. Mill, L. Paradowski, R. Lackner et al., Improved results of lung transplantation for patients with cystic fibrosis, The Journal of Thoracic and Cardiovascular Surgery, vol.109, issue.2, pp.224-234, 1995.
DOI : 10.1016/S0022-5223(95)70383-7

I. Inci, O. Stanimirov, C. Benden, P. Kestenholz, M. Hofer et al., Lung transplantation for cystic fibrosis: a single center experience of 100 consecutive cases, European Journal of Cardio-Thoracic Surgery, vol.41, issue.2, pp.435-475, 2012.
DOI : 10.1016/j.ejcts.2011.06.017

P. Flume, T. Egan, L. Paradowski, F. Detterbeck, J. Thompson et al., Infectious complications of lung transplantation. Impact of cystic fibrosis., American Journal of Respiratory and Critical Care Medicine, vol.149, issue.6, pp.1601-1608, 1994.
DOI : 10.1164/ajrccm.149.6.7516251

R. Kotloff and J. Zuckerman, Lung Transplantation for Cystic Fibrosis, Chest, vol.109, issue.3, pp.787-98, 1996.
DOI : 10.1378/chest.109.3.787

D. Cockcroft and M. Gault, Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976.
DOI : 10.1159/000180580

N. Soulsby, H. Greville, K. Coulthard, and C. Doecke, What is the best method for measuring renal function in adults and children with cystic fibrosis?, Journal of Cystic Fibrosis, vol.9, issue.2, pp.124-133, 2010.
DOI : 10.1016/j.jcf.2009.12.002

X. Publications, B. Coltey, I. Pin, G. Ferretti, A. Bonadona et al., Allergic bronchopulmonary aspergillosis disclosing mucoviscidosis], Rev Mal Respir, 2001.

B. Ø?-de-winter, C. Monchaud, A. Prémaud, C. Pison, R. Kessler et al., Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients, Clinical Pharmacokinetics, vol.31, issue.3
DOI : 10.2165/11594050-000000000-00000

Ø. Costache, V. Chavanon, O. St-raymond, C. Sessa, C. Durand et al., Dramatic Improvement in Survival After Lung Transplantation Over Time: A Single Center Experience, Transplantation Proceedings, vol.41, issue.2, pp.687-91, 2009.
DOI : 10.1016/j.transproceed.2008.12.016

URL : https://hal.archives-ouvertes.fr/inserm-00387548

Ø. Reynaud-gaubert, M. Pison, C. Stern, M. Haloun, A. Velly et al., Indications for lung and heart -lung transplantation in adults

Ø. Thabut, G. Mal, H. Cerrina, J. Dartevelle, P. Dromer et al., Influence of Donor Characteristics on Outcome After Lung Transplantation: A Multicenter Study, The Journal of Heart and Lung Transplantation, vol.24, issue.9, pp.1347-53, 2005.
DOI : 10.1016/j.healun.2004.10.016

Ø. Quétant, S. Rochat, T. Pison, and C. , [Results of lung transplantation], Rev Mal Respir, 2010.